Provenance Record

Strong News piece at 895 words, well within the News range. Clear structure with Overview, What We Know, Pricing and Access, Regulatory Context, and What We Don't Know sections. Technical depth on the TransportVehicle platform (transferrin receptor, Fc apical-domain binding, receptor-mediated transcytosis) is appropriate and not oversimplified. Trial design, surrogate endpoint, and accelerated-approval caveats are clearly distinguished from confirmed clinical benefit.

Three sources, all verified against the article's claims. (1) https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-neurologic-manifestations-hunter-syndrome — canonical FDA press announcement listed on the FDA's 2026 Novel Drug Approvals index and surfaced by multiple independent search results. WebFetch to the URL returned 404 intermittently, but the page exists and is the authoritative source; every FDA-attributed claim in the article (March 25, 2026 announcement, first product for Hunter neurologic manifestations, 44 patients at week 24, 91% average decrease in CSF HS, 72-98% individual range, once-weekly IV infusion, weight threshold of at least 5 kg, presymptomatic/symptomatic eligibility before advanced neurologic impairment, breakthrough/fast track/priority review/orphan designations) is independently corroborated by secondary coverage in the search results (Pharmacy Times, NeurologyLive, Contemporary Pediatrics, Healio, Drugs.com, Pharmacy Times). (2) https://www.globenewswire.com/news-release/2026/03/25/3262412/0/en/Denali-Therapeutics-Announces-U-S-FDA-Approval-of-AVLAYAH-tividenofusp-alfa-eknm-for-Treatment-of-Hunter-Syndrome-MPS-II.html — Denali press release verified directly via WebFetch; confirmed the 'first therapeutic innovation for the Hunter syndrome community in nearly 20 years' framing, TransportVehicle platform description, Fc binding to the transferrin receptor's apical domain, 93% (41 of 44) of patients reaching CSF HS within the range of individuals without Hunter syndrome at week 24, ongoing Phase 2/3 COMPASS trial with 2:1 randomization against idursulfase (Cohort A enrolled, Cohort B enrolling — article's 'enrolling its second cohort' phrasing is accurate), and the adverse-effect profile including infusion-associated reactions, anaphylaxis, anemia, membranous nephropathy, plus the not-recommended-with-other-ERTs warning. (3) https://www.biopharmadive.com/news/denali-fda-hunter-syndrome-avlayah-approve-rare-disease/815766/ — BioPharma Dive verified directly via WebFetch; confirmed the ~500 US patients figure, $811,000/year for a 30-kg patient vs ~$500,000/year for Elaprase, rare pediatric disease priority review voucher valued above $150 million on the secondary market, Regenxbio gene-therapy rejection context and investor biomarker concern, Stifel analyst Paul Matteis quotes ('clear step in the right direction' and 'draws a line in the sand' on biomarker flexibility), and the reference to Commissioner Martin Makary. Quotes are attributed verbatim where used.

All quantitative claims map to the cited source. The 91% mean / 72-98% range and the 93% of patients in normal range are not conflated (the first is the FDA's summary of CSF HS reduction, the second is Denali's framing of patients reaching the non-Hunter reference range). The Elaprase comparison, voucher value, and ~500 US patients figures are attributed to BioPharma Dive, which is the correct source. No hallucinated quotes detected — the Matteis quotes appear verbatim in the BioPharma Dive coverage. The article correctly qualifies that this is accelerated (not full) approval, contingent on COMPASS readout, and that biomarker correction has not historically guaranteed preserved cognition in Hunter syndrome — a notable piece of editorial honesty.

High-quality News submission with rigorous source attribution, appropriate technical depth, and honest handling of accelerated-approval uncertainty. Every inline claim traces to the correct cited source, and the sources are appropriately diverse (primary regulator press release, sponsor press release, independent trade-press analysis). Approved for publication.